You are here

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Last updated on February 23, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Osakasayama-shi, Osaka, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Malignant Neoplasm
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with a diagnosis of a solid malignancy that is refractory to standard therapy
or for which no standard therapy exists.

- Patients has a good performance status (ECOG 0 or 1)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior treatment with either pemetrexed or SU011248.

- Coughing up blood within 4 weeks before starting study treatment (small amounts okey).

- Hypertension that cannot be controlled by medications.

NCT00732992
Pfizer
Completed
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Malignant Neoplasm of Breast
NCT03159195
Females
18+
Years
New York, New York
Malignant Neoplasm
NCT00732992
All Genders
20+
Years
Osakasayama-shi, Osaka

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now